.....The reason CSL112 isn't listed as 40/50% like the typical cardiovascular drug is due to the lacklustre Phase 2 results and the Pfizer Phase 3 results of a similar drug:....
Yeah, that's what he says in the report, however CSL is wall-to-wall PhDs, and this Goldman Sachs guy is a medical student intern. I mean.......seriously...?
No disrespect intended, but I know who I'm listening to.
.....The reason CSL112 isn't listed as 40/50% like the typical...
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$292.00 |
Change
-1.690(0.58%) |
Mkt cap ! $141.3B | |||
| Open | High | Low | Value | Volume |
| $292.05 | $294.47 | $290.89 | $107.0M | 366.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 278 | $291.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $292.00 | 366 | 1 |
View Market Depth
| Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
| CSL (ASX) Chart |